Is phosphoproteomics ready for clinical research?

被引:16
作者
Iliuk, Anton B.
Tao, W. Andy [1 ]
机构
[1] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
基金
美国国家卫生研究院; 美国食品与农业研究所;
关键词
Phosphoproteomics; Mass spectrometry; Signaling; TYROSINE KINASE INHIBITOR; BCR-ABL; PROTEOMIC ANALYSES; GENE-EXPRESSION; LEUKEMIA; CANCER; PATHWAYS; THERAPY; RESISTANCE; MEDICINE;
D O I
10.1016/j.cca.2012.10.063
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: For many diseases such as cancer where phosphorylation-dependent signaling is the foundation of disease onset and progression, single-gene testing and genomic profiling alone are not sufficient in providing most critical information. The reason for this is that in these activated pathways the signaling changes and drug resistance are often not directly correlated with changes in protein expression levels. In order to obtain the essential information needed to evaluate pathway activation or the effects of certain drugs and therapies on the molecular level, the analysis of changes in protein phosphorylation is critical. Methods: Existing approaches do not differentiate clinical disease subtypes on the protein and signaling pathway level, and therefore hamper the predictive management of the disease and the selection of therapeutic targets. Conclusions: The mini-review examines the impact of emerging systems biology tools and the possibility of applying phosphoproteomics to clinical research. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 48 条
  • [1] Phosphoproteomic Analysis of Leukemia Cells under Basal and Drug-treated Conditions Identifies Markers of Kinase Pathway Activation and Mechanisms of Resistance
    Alcolea, Maria P.
    Casado, Pedro
    Rodriguez-Prados, Juan-Carlos
    Vanhaesebroeck, Bart
    Cutillas, Pedro R.
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2012, 11 (08) : 453 - 466
  • [2] Andersen J, 2010, DANCING TIMES, V100, P55
  • [3] SELECTIVE-INHIBITION OF THE PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION PATHWAY BY A PROTEIN-TYROSINE KINASE INHIBITOR OF THE 2-PHENYLAMINOPYRIMIDINE CLASS
    BUCHDUNGER, E
    ZIMMERMANN, J
    METT, H
    MEYER, T
    MULLER, M
    REGENASS, U
    LYDON, NB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) : 2558 - 2562
  • [4] Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
    Carayol, Nathalie
    Vakana, Eliza
    Sassano, Antonella
    Kaur, Surinder
    Goussetis, Dennis J.
    Glaser, Heather
    Druker, Brian J.
    Donato, Nicholas J.
    Altman, Jessica K.
    Barr, Sharon
    Platanias, Leonidas C.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (28) : 12469 - 12474
  • [5] Harnessing synthetic lethal interactions in anticancer drug discovery
    Chan, Denise A.
    Giaccia, Amato J.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) : 351 - 364
  • [6] Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
    Chen, Rui
    Mias, George I.
    Li-Pook-Than, Jennifer
    Jiang, Lihua
    Lam, Hugo Y. K.
    Chen, Rong
    Miriami, Elana
    Karczewski, Konrad J.
    Hariharan, Manoj
    Dewey, Frederick E.
    Cheng, Yong
    Clark, Michael J.
    Im, Hogune
    Habegger, Lukas
    Balasubramanian, Suganthi
    O'Huallachain, Maeve
    Dudley, Joel T.
    Hillenmeyer, Sara
    Haraksingh, Rajini
    Sharon, Donald
    Euskirchen, Ghia
    Lacroute, Phil
    Bettinger, Keith
    Boyle, Alan P.
    Kasowski, Maya
    Grubert, Fabian
    Seki, Scott
    Garcia, Marco
    Whirl-Carrillo, Michelle
    Gallardo, Mercedes
    Blasco, Maria A.
    Greenberg, Peter L.
    Snyder, Phyllis
    Klein, Teri E.
    Altman, Russ B.
    Butte, Atul J.
    Ashley, Euan A.
    Gerstein, Mark
    Nadeau, Kari C.
    Tang, Hua
    Snyder, Michael
    [J]. CELL, 2012, 148 (06) : 1293 - 1307
  • [7] BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells
    Chu, S
    Holtz, M
    Gupta, M
    Bhatia, R
    [J]. BLOOD, 2004, 103 (08) : 3167 - 3174
  • [8] Cox David M, 2005, J Biomol Tech, V16, P83
  • [9] Assay Development for the Determination of Phosphorylation Stoichiometry Using Multiple Reaction Monitoring Methods with and without Phosphatase Treatment: Application to Breast Cancer Signaling Pathways
    Domanski, Dominik
    Murphy, Leigh C.
    Borchers, Christoph H.
    [J]. ANALYTICAL CHEMISTRY, 2010, 82 (13) : 5610 - 5620
  • [10] Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
    Druker, BJ
    Lydon, NB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) : 3 - 7